04.13.16
Quotient Clinical has expanded its clinical spray drying capability to overcome drug compound solubility issues with the acquisition of a Niro Mobile Minor Spray Dryer. The addition of a larger scale spray dryer allows for the production of a range of batch sizes, from milligrams up to two kilograms.
Situated at Quotient’s new GMP facility at MediCity in Nottingham, UK (scheduled to open later in 2016), this expansion aims to address customer needs for ongoing product development support, including toxicology and later stage clinical studies.
Nikki Whitfield, vice president of Pharmaceutical Sciences, said, “Poor solubility is increasingly prevalent in drug pipelines across the industry. We have established a broad suite of formulation approaches within our Translational Pharmaceutics platform to addressthese complex solubility and bioavailability challenges, and this latest investment will allow us to efficiently scale up the production of optimized formulations to support our clients’ downstream clinical development programs.”
Situated at Quotient’s new GMP facility at MediCity in Nottingham, UK (scheduled to open later in 2016), this expansion aims to address customer needs for ongoing product development support, including toxicology and later stage clinical studies.
Nikki Whitfield, vice president of Pharmaceutical Sciences, said, “Poor solubility is increasingly prevalent in drug pipelines across the industry. We have established a broad suite of formulation approaches within our Translational Pharmaceutics platform to addressthese complex solubility and bioavailability challenges, and this latest investment will allow us to efficiently scale up the production of optimized formulations to support our clients’ downstream clinical development programs.”